Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Stocks | Futures | Watchlist | More
or

Pfizer Inc (PFE)

Pfizer Inc (PFE)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 224,187,312
  • Shares Outstanding, K 5,534,123
  • Annual Sales, $ 53,647 M
  • Annual Income, $ 11,152 M
  • 60-Month Beta 0.65
  • Price/Sales 4.39
  • Price/Cash Flow 9.64
  • Price/Book 3.44

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 10 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/19
See More
  • Average Estimate 0.57
  • Number of Estimates 4
  • High Estimate 0.59
  • Low Estimate 0.55
  • Prior Year 0.64
  • Growth Rate Est. (year over year) -10.94%

Price Performance

See More
Period Period Low Period High Performance
1-Month
38.64 +4.84%
on 12/18/19
40.87 -0.88%
on 01/15/20
+1.61 (+4.14%)
since 12/17/19
3-Month
36.22 +11.84%
on 10/23/19
40.87 -0.88%
on 01/15/20
+4.05 (+11.11%)
since 10/17/19
52-Week
33.97 +19.25%
on 08/15/19
44.56 -9.09%
on 07/03/19
-1.96 (-4.62%)
since 01/17/19

Most Recent Stories

More News
AstraZeneca Announces Positive FDA Updates on Cancer Drugs

AstraZeneca's (AZN) label expansion application for Lynparza in a prostate cancer indication gets priority review from the FDA. Imfinzi and pipeline candidate, tremelimumab get orphan drug status for liver...

JNJ : 149.17 (+0.65%)
AZN : 51.33 (+1.62%)
PFE : 40.51 (-0.25%)
RHHBY : 42.4200 (+1.60%)
Genital Herpes Treatment Market is expected to register a CAGR of 4.4% of during 2017-2027

ABT : 89.00 (+0.82%)
GSK : 47.89 (+1.55%)
NVS : 95.93 (+0.87%)
PFE : 40.51 (-0.25%)
VRX.TO : 30.80 (-3.33%)
Thinking about buying stock in Advanced Micro Devices, Canopy Growth Corp, Fitbit, Pfizer, or Snap?

InvestorsObserver issues critical PriceWatch Alerts for AMD, CGC, FIT, PFE, and SNAP.

AMD : 50.93 (+2.33%)
CGC : 24.89 (+2.43%)
FIT : 6.68 (+1.37%)
PFE : 40.51 (-0.25%)
SNAP : 19.11 (+4.71%)
Serine Threonine Protein Kinase ATR, Pipeline Review, H2 2019 - Artios Pharma Ltd, Bayer AG, IMPACT Therapeutics Inc & Pfizer Inc - ResearchAndMarkets.com

The "Serine Threonine Protein Kinase ATR - Pipeline Review, H2 2019" drug pipelines has been added to ResearchAndMarkets.com's offering.

BAYRY : 20.9350 (-0.21%)
PFE : 40.51 (-0.25%)
Novo Nordisk's Ozempic Gets FDA Nod for CV Risk Reduction

Novo Nordisk's (NVO) Ozempic gets FDA approval for reducing the risk of major adverse cardiovascular events in people with type II diabetes and established CVD.

PFE : 40.51 (-0.25%)
LLY : 139.58 (-1.31%)
NVO : 61.31 (unch)
GILD : 62.98 (-0.35%)
Ophthalmic Drugs Market Size, Share, Challenges, Threats, Development and Global Trend Analysis till 2029n

A recent market research analysis titled, Ophthalmic Drugs Market offers insightful information to the clients escalating their basic leadership size explores distinct significant facets associated with...

AGN : 192.68 (-0.59%)
NVS : 95.93 (+0.87%)
PFE : 40.51 (-0.25%)
REGN : 385.94 (+0.10%)
SNPHF : 17.2500 (+2.68%)
SHPG : 179.20 (+4.10%)
TEVA : 10.20 (-3.95%)
VRX.TO : 30.80 (-3.33%)
Bristol-Myers' Opdivo-Yervoy sBLA for NSCLC Accepted by FDA

The FDA accepts Bristol-Myers' (BMY) sBLA for the Opdivo-Yervoy combo for the first-line treatment of patients with metastatic or recurrent NSCLC with no EGFR or ALK genomic tumor aberrations.

MRK : 90.97 (-0.23%)
BMY : 66.72 (-0.09%)
LLY : 139.58 (-1.31%)
PFE : 40.51 (-0.25%)
Histone Lysine N Methyltransferase EZH2, Pipeline Review, H2 2019 - Domainex Ltd, Kainos Medicine Inc, Epizyme Inc & Pfizer Inc - ResearchAndMarkets.com

The "Histone Lysine N Methyltransferase EZH2 - Pipeline Review, H2 2019" drug pipelines has been added to ResearchAndMarkets.com's offering.

EPZM : 26.72 (+4.62%)
PFE : 40.51 (-0.25%)
Varicella Zoster Infection Treatment Market is Expected to Register a 4.2% CAGR from 2017 to 2027

Future Market Insights (FMI) has published a new report on the varicella zoster infection treatment market titled Varicella zoster infection comprises two main types namely varicella chickenpox and herpes...

ABT : 89.00 (+0.82%)
GSK : 47.89 (+1.55%)
NVS : 95.93 (+0.87%)
PFE : 40.51 (-0.25%)
TEVA : 10.20 (-3.95%)
VRX.TO : 30.80 (-3.33%)
Herpes Labialis Treatment Market to Record CAGR of 4.6% Increase in Revenue by 2027 | FMI

Attributed to rising penetration of generics and innovations in disease treatment, the US$ 869.3 Mn global herpes labialis treatment market is anticipated to expand at a CAGR of 4.6% over 2017-2027, attaining...

ABT : 89.00 (+0.82%)
NVS : 95.93 (+0.87%)
PFE : 40.51 (-0.25%)
TEVA : 10.20 (-3.95%)
VRX.TO : 30.80 (-3.33%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 72% Buy with a Average short term outlook on maintaining the current direction.

The market is approaching overbought territory. Be watchful of a trend reversal.

See More Share

Trade PFE with:

Business Summary

Pfizer Inc. is a research-based, global pharmaceutical company that discovers, develops, manufactures, and markets medicines for humans and animals. The Company's diversified global healthcare portfolio includes human and animal biologic and small molecule medicines and vaccines, as well as nutritional...

See More

Key Turning Points

2nd Resistance Point 40.96
1st Resistance Point 40.74
Last Price 40.51
1st Support Level 40.35
2nd Support Level 40.19

See More

52-Week High 44.56
Fibonacci 61.8% 40.52
Last Price 40.51
Fibonacci 50% 39.27
Fibonacci 38.2% 38.02
52-Week Low 33.97

See More

Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar